Skip to main content

UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel

November 02, 2018 | Joanne Morrison

Kathleen Neuzil, MD, MPH

Dr. Kathleen Neuzil Will be Only U.S. Member to Serve on WHO Strategic Advisory Group of Experts on Immunization (SAGE)

Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.

Dr. Neuzil’s term, which was approved by the Director-General of the WHO, will be effective from January 2019 through December 2021. SAGE was established by the Director-General of the WHO in 1999 to provide guidance on the work of WHO. SAGE is the principal advisory group to WHO for vaccines and immunization and advises WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. SAGE is concerned not just with childhood vaccines and immunization, but all vaccine-preventable diseases.

“I am honored to serve on SAGE and to contribute to better health for children around the world through thoughtful, evidence-based global health policy. Assuring access to vaccines in the world’s poorest countries is my passion and can save millions of lives,” said Dr. Neuzil.

Dr. Neuzil is uniquely positioned to contribute to the mission of SAGE. She has dedicated her career to reducing and eliminating vaccine-preventable diseases in children and adults. As an academic, Dr. Neuzil has published extensively in the field of vaccinology, and her research has informed health policy and advanced vaccine programs throughout the world. Dr. Neuzil is currently leading the Typhoid Vaccine Acceleration Consortium (TyVAC) to bring much-needed typhoid vaccines to Africa and Asia.

‌‌Dr. Neuzil is likewise experienced in the vaccine policy realm, having served as a member of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices for many years and in a number of other vaccine policy roles for professional, governmental, and global organizations. She previously served as a technical advisor to WHO on influenza, diarrheal diseases, vaccine safety, and maternal immunization.

“Dr. Neuzil has decades of experience in vaccines and infectious disease research and global health program implementation. She will bring her expertise, energy, and passion to this new role as a member of SAGE,” said UMSOM Dean E. Albert Reece, MD, PhD, MBA, who is also the Executive Vice President for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $530 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/

About the UMSOM Center for Vaccine Development and Global Health 

For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases.

CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eradicate diseases of global impact. Currently, these diseases include malaria, typhoid, shigella and vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Zika and Ebola. In addition, CVD’s work focuses on the ever-growing challenge of anti-microbial resistance. 

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Tuesday, May 21, 2024

    University of Maryland School of Medicine Launches Vaccine Development Program to Prevent Sepsis in Newborns

    University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded up to $3.96 million over three years to develop and test a vaccine in an animal model that could eventually be used in pregnant women to prevent sepsis in newborns and infants.


    Thursday, March 28, 2024

    NIH selects Dr. Kathleen Neuzil as Director of The Fogarty International Center

    Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.


    Monday, July 18, 2022

    New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field

    Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.


    Wednesday, January 26, 2022

    Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing

    A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).


    Friday, February 05, 2021

    UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests

    Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.


    Thursday, July 02, 2020

    UMSOM Researchers Help Weigh Role of Human Challenge Studies for COVID-19 Vaccine Development

    Members of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, which includes Kathleen Neuzil, MD, MPH, DTPH, the Myron M. Levine, MD, DTPH Professor in Vaccinology and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), assessed the practical considerations and prerequisites for using controlled human infection models (CHIMs) to support development of a SARS-CoV-2 Vaccine.


    Tuesday, December 10, 2019

    UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water

    Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.


    Wednesday, October 30, 2019

    UM School of Medicine's Myron M. Levine, MD, DTPH, to Receive Prestigious Lifetime Award for Five Decades of Pioneering Vaccine Research

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor at the University of Maryland School of Medicine (UMSOM), Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founder and Former Director of the Center for Vaccine Development and Global Health (CVD) is a co-recipient of the 2020 Research! America Geoffrey Beene Foundation Builders of Science Award for his pioneering vaccine and infectious disease research.


    Thursday, October 24, 2019

    Dr. James Campbell Makes Baltimore Magazine’s 2019 “Top Docs” List

    Dr. Campbell is a pediatric infectious disease specialist conducting important vaccine research


    Monday, October 21, 2019

    UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine

    Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization. Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.


    Friday, September 20, 2019

    UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research

    Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.


    Tuesday, August 13, 2019

    UM School of Medicine Researchers Begin Phase 1 Clinical Trial of Vaccine Against Mosquito-Borne Diseases

    Mosquito-borne diseases including malaria, dengue and yellow fever, have a severe impact resulting in millions of deaths worldwide, hitting the world’s most vulnerable populations the hardest. Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental vaccine that is designed to protect against a series of these diseases.


    Wednesday, July 17, 2019

    Vaccines Tested in UM School of Medicine’s Center for Vaccine Development Protect Children Around the World

    For 30 years, the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) has collaborated with the Pediatric Center of Frederick to test vaccines used in pediatric care.


    Sunday, October 28, 2018

    American Society of Tropical Medicine & Hygiene Awards Dr. Miriam Laufer the LePrince Medal for Malaria Research

    Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director for Malaria Research at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), was awarded the Joseph Augustin LePrince Medal by the American Society of Tropical Medicine and Hygiene (ASTMH).


    Wednesday, June 06, 2018

    UMSOM Researchers Find that Silent Carriers of Malaria are Unlikely to Develop the Disease

    In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.


    Tuesday, May 15, 2018

    Tackling Malaria Transmission in Sub-Saharan Africa

    Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.


    Friday, May 11, 2018

    Honoring Dr. Robert Edelman for Three Decades of Service at UMSOM

    Dr. Robert Edelman’s legacy will live long past his tenure at the Center for Vaccine Development and Global Health (CVD). Prior to an esteemed career in academia, he served in the military and the US public health service.


    Thursday, May 03, 2018

    Low Efficacy Influenza Vaccines Can Still Significantly Avert Infections, Study Shows

    Research published in PNAS, showed that even less effective influenza vaccines can still help to reduce illnesses, hospitalizations and other issues as long as the vaccine is broadly administered across age groups.


    Monday, April 23, 2018

    UM School of Medicine Launches Newly Organized Center for Vaccine Development and Global Health Under Leadership of International Vaccine Expert Dr. Kathleen Neuzil

    University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a newly organized Center for Vaccine Development and Global Health (CVD). The new Center will be led by UMSOM Professor of Medicine and Pediatrics, Kathleen Neuzil, MD MPH, FIDSA, one of the world’s most influential research scientists and advocates in vaccine development and policy.